Company Name, Ticker, Competitors, else..

Minerva Neurosciences Inc (NASDAQ: NERV)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Minerva Neurosciences Inc 's

Name: Minerva Neurosciences Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NERV Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Minerva Neurosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 38.45 %, recorded in the same quarter.

• List of NERV Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Minerva Neurosciences Inc achieved net profit of $16.65 millions compared to a net loss of $-3.26 millions recorded in the same quarter a year ago.

<< NERV Stock Performance Comparisons

<< See the full list of NERV competitors

*Market share is calculated based on total revenue.

NERV's Stock Performance relative to its Competitors

Publicly Traded Peers of Minerva Neurosciences Inc

Boundless Bio Inc
Share Performance

+132.79%

This Year

Boundless Bio Inc

Profile

Audentes Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative gene therapies for serious rare diseases. Their business model revolves around conducting extensive research and development to design and produce these gene therapies. They then collaborate with healthcare providers and regulatory bodies to gain necessary approvals and commercialize their therapies, aiming to provide effective treatments for patients suffering from rare diseases.

More about Boundless Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 63.758 mill.	$ - mill.	$ -64.012 mill.

Entrada Therapeutics Inc
Share Performance

-35.62%

This Year

Entrada Therapeutics Inc

Profile

Entrada Therapeutics Inc is a biotechnology company that focuses on developing transformative therapies for various diseases. Their business model involves utilizing their proprietary platform to design and develop cell-penetrating peptides to deliver therapeutic molecules into cells. By leveraging their innovative technology, they aim to bring novel treatments to patients and ultimately improve health outcomes.

More about Entrada Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 273.174 mill.	$ 4.686 mill.	$ 33.879 mill.

Neurocrine Biosciences Inc
Share Performance

-1.14%

Over The Past 5 Days

Neurocrine Biosciences Inc

Profile

Neurocrine Biosciences Inc's business model involves researching, developing, and commercializing innovative therapies for neurological and endocrine disorders.

More about Neurocrine Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 16,311.989 mill.	$ 3,373.900 mill.	$ 705.500 mill.

Sage Therapeutics Inc
Share Performance

0.00%

30 Days

Sage Therapeutics Inc

Profile

Sage Therapeutics Inc's business model primarily revolves around researching, developing, and commercializing innovative therapies for various central nervous system disorders. The company focuses on discovering novel molecules and applying them to create targeted treatments that address the unmet medical needs of patients. By harnessing scientific advancements and strategic collaborations, Sage aims to deliver transformative therapies for individuals suffering from conditions such as depression, postpartum depression, and other mood disorders.

More about Sage Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 543.460 mill.	$ 70.410 mill.	$ -301.195 mill.

Uniqure N v
Share Performance

+68.35%

This Quarter

Uniqure N v

Profile

Uniqure N.V's business model revolves around developing and commercializing gene therapies to address rare genetic diseases.

More about Uniqure N v 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,794.880 mill.	$ 18.093 mill.	$ -208.869 mill.

4 more competitors available

Sources: Minerva Neurosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 6:22 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Minerva Neurosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.